New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 3mg (as a mannitol boronic ester) - powder for injection - 3 mg - active: bortezomib 3mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 3mg (as a mannitol boronic ester) - powder for injection - 3 mg - active: bortezomib 3mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Canada - English - Health Canada

pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3mg - bortezomib (bortezomib mannitol boronic ester) 3mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - bortezomib

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bortezomib as mannitol boronic ester - powder for solution for injection - bortezomib as mannitol boronic ester 3.5 mg - bortezomib - multiple myelomabortezomib s.k is indicated for the treatment of patients with multiple myeloma.mantle cell lymphomabortezomib s.k is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.bortezomib s.k in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 1mg - bortezomib (bortezomib mannitol boronic ester) 1mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents